MarketPulse

Phase 1

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Kymera Therapeutics Advances IBD Pipeline With Promising KT-579 Preclinical Data

Kymera Therapeutics showcases KT-579 preclinical data matching approved IBD therapies ahead of Phase 1 trials in late 2026.
KYMRclinical trialinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Radiopharm Theranostics

Radiopharm Theranostics Advances Pipeline as Cash Dwindles to $19.2M

Radiopharm completes Phase 2b enrollment for brain imaging agent RAD 101 with 90% MRI concordance, initiates new trials while cash reserves fall sharply.
RADXclinical trialsradiopharmaceuticals
GlobeNewswire Inc.GlobeNewswire Inc.··Jade Biosciences, Inc.

Jade Biosciences Posts $127.4M Loss, Eyes 2028 Cash Runway With Pipeline Catalysts

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.
JBIOmonoclonal antibodyclinical trials